Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCL
In Partnership With:
Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.
Peter Riedell, MD, assistant professor of medicine, University of Chicago Medicine, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma (MCL).
MCL is a rare subtype of non-Hodgkin lymphoma in which survival outcomes are heterogenous, Riedell says. For most patients, the standard treatment approach includes intensive induction therapy followed by consolidative autologous stem cell transplant. However, some patients do not derive long-term benefit from this regimen, Riedell explains.
As such, during the 2021 ASCO Annual Meeting, findings from a study evaluating the effect of time to relapse on overall survival in patients with MCL who underwent this frontline therapeutic approach were presented, Riedell concludes.
